pSELECT-NHA-blasti

Plasmid for the expression of human influenza hemagglutinin (HA)-N-terminal tagged proteins

Catalog code: psetb-nha

https://www.invivogen.com/pselect-ha-tag

For research use only

Version 2I17-MM

PRODUCT INFORMATION

Contents

- 20 µg of **pSELECT-NHA-blasti** plasmid provided as lyophilized DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pSELECT plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfectants and offer a variety of selectable markers. pSELECT plasmids contain two expression cassettes: the first drives the expression of the gene of interest and the second drives the expression of a large choice of dominant selectable markers for both *E. coli* and mammalian cells. They are both terminating with a strong polyadenylation signal (polyA) that separates the two expression cassettes thus preventing any transcription interference. The late SV40 polyA terminates the transcription of the gene of interest while the human β-globin polyA terminates the transcription of the selectable marker.

pSELECT-Tag is a new family of expression plasmids designed to generate tagged proteins in order to facilitate their detection and/or purification. pSELECT-Tag features three well-known tags: the green fluorescent protein (GFP) gene, the human influenza hemagglutinin (HA) epitope and the polyhistidine (His) tag. pSELECT-Tag plasmids allow to add the tag either at the N or C terminus of the protein of interest. The N-terminal tag: the tag encompasses the Start codon and is followed by a multiple cloning site (MCS).

PLASMID FEATURES

First expression cassette

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter[1] and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat[2]. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS:** The multiple cloning site contains the following restriction sites: 5' - Age I, Sal I, , Eco47 III, Nco I, BamH I - 3'
Each restriction site is compatible with many other enzymes.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA[3].
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Blasti:** Resistance to Blasticidin S is conferred by the *bsr* gene from *Bacillus cereus*. The *bsr* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.
- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription[4].

CLONING STRATEGY

For expression of a tagged protein, it is important to ensure to clone your gene-of-interest into the correct reading frame. In general it is recommended to use BamHI/NheI restriction site combination for cloning into plasmids with the N-Tag. For the plasmids with N-Tag, check whether your gene of interest and the start codon of the N-tag are in the correct reading frame.

Note: The Bam HI restriction site is compatible with BglII.

If it is not possible to use the NheI restriction site, it is possible to use another restriction site such as NcoI.



Alternatively, blunt end cloning can be achieved using the Eco47III site, which is downstream of the BamHI site. Blunt end PCR fragments can be obtained using T4 DNA polymerase or Klenow.



TECHNICAL SUPPORT
InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3622-3480
E-mail: info@invivogen.com

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H_2O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

References:

1. Kim, D.W. et al., 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 2: 217-223. **2. Takebe, Y. et al., 1988. S**R alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell Biol. 1: 466-472. **3. Carswell, S., & Alwine, J.C., 1989.** Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences.Mol. Cell Biol. 10: 4248-4258. **4. Yu J & Russell JE., 2001.** Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA.Mol Cell Biol, 21(17):5879-88.

RELATED PRODUCTS

Product	Catalog Code
pSELECT-NGFP-blasti	psetb-ngfp
pSELECT-CGFP-blasti	psetb-cgfp
pSELECT-NGFP-zeo	psetz-ngfp
pSELECT-CGFP-zeo	psetz-cgfp
pSELECT-CHA-blasti	psetb-cha
pSELECT-NHA-zeo	psetz-nha
pSELECT-CHA-zeo	psetz-cha
pSELECT-NHis-zeo	psetz-nhis
pSELECT-CHis-blasti	psetb-chis


PacI (3273)
NotI (-1)
HindIII (410)
ApaLI (2857)
pMB1 ori
hEF1/HTLV prom
BspLU11I (2543)
PacI (2533)
SdaI (2525)
AgeI (717)
BspLU11I (725)
HA-tag
pSELECT-NHA-blasti
(3292 bp)
MCS
BamHI (817)
Eco47III (823)
NcoI (833)
NheI (839)
SV40 pAn
hCMV enh/prom
ßGlo pAn
EcoRI (1073)
EM7
Bsr
SpeI (2114)
AseI (1959)
BspHI (1901)


NotI (-1)
1 GCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAACATAC
75 GCTCTCCATCAAAACAAAACGAAACAAAACAAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCAGGTGCCAG
149 AACATTTCTCTATCGAAGGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCC
223 CCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGT
297 GATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAA
HindIII (410)
371 CGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCG
445 CCCGCCGCCCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCCTCC
519 TGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAG
593 CCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTT
BspLU11I (725)
AgeI (717)
667 CTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGTCAACATGTATCCCTATG
1 MetTyrProTyrA
741 ATGTGCCAGACTATGCTGGCTATCCATATGATGTTCCTGATTATGCTGGATACCCTTATGATGTGCCAGACTAT
5 spValProAspTyrAlaGlyTyrProTyrAspValProAspTyrAlaGlyTyrProTyrAspValProAspTyr
Eco47III (823)
NheI (839)
BamHI (817)
NcoI (833)
815 GCCGGATCCAGCGCTGCAGCCATGGGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCA
30 AlaGlySer
889 CAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATA
963 AGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGT
EcoRI (1073)
1037 TTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAAACTTTAACCTCC
1111 AAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGC
1185 ATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAGATATAGTGTATTTTCCCAAGGTTTGAACTAGCT
1259 CTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAA
1333 ATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGGCCCTTCATAATATCCC
1407 CCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAG
1481 CTTTAGTTCCTGGTGTACTTGAGGGGGATGAGTTCCTCAATGGTGGTTTTGACCAGCTTGCCATTCATCTCAAT
141 •••AsnArgThrTyrLysLeuProIleLeuGluGluIleThrThrLysValLeuLysGlyAsnMetGluIle
1555 GAGCACAAAGCAGTCAGGAGCATAGTCAGAGATGAGCTCTCTGCACATGCCACAGGGGCTGACCACCCTGATGG
117 LeuValPheCysAspProAlaTyrAspSerIleLeuGluArgCysMetGlyCysProSerValValArgIleSe
1629 ATCTGTCCACCTCATCAGAGTAGGGGTGCCTGACAGCCACAATGGTGTCAAAGTCCTTCTGCCCGTTGCTCACA
92 rArgAspValGluAspSerTyrProHisArgValAlaValIleThrAspPheAspLysGlnGlyAsnSerValA
1703 GCAGACCCAATGGCAATGGCTTCAGCACAGACAGTGACCCTGCCAATGTAGGCCTCAATGTGGACAGCAGAGAT
67 laSerGlyIleAlaIleAlaGluAlaCysValThrValArgGlyIleTyrAlaGluIleHisValAlaSerIle
1777 GATCTCCCCAGTCTTGGTCCTGATGGCCGCCCCGACATGGTGCTTGTTGTCCTCATAGAGCATGGTGATCTTCT
43 IleGluGlyThrLysThrArgIleAlaAlaGlyValHisHisLysAspAspGluTyrLeuMetThrIleLysGl


BspHI (1901)
1851 CAGTGGCGACCTCCACCAGCTCCAGATCCTGCTGAGAGATGTTGAAGGTCTTCATGATGGCCCTCCTATAGTGA
18 uThr Al aVal GluVal LeuGluLeuAspGlnGlnSer I leAsnPheThr LysMet
AseI (1959)
1925 GTCGTATTATACTATGCCGATATACTATGCCGATGATTAATTGTCAAAACAGCGTGGATGGCGTCTCCAGCTTA
1999 TCTGACGGTTCACTAAACGAGCTCTGCTTATATAGACCTCCCACCGTACACGCCTACCGCCCATTTGCGTCAAT
SpeI (2114)
2073 GGGGCGGAGTTGTTACGACATTTTGGAAAGTCCCGTTGATTTACTAGTCAAAACAAACTCCCATTGACGTCAA
2146 TGGGGTGGAGACTTGGAAATCCCCGTGAGTCAAACCGCTATCCACGCCCATTGATGTACTGCCAAAACCGCATC
2220 ATCATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCCATAAGGTCATGTACTGGGC
2294 ATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTA
2368 CTGCCAAGTGGGCAGTTTACCGTAAATACTCCACCCATTGACGTCAATGGAAAGTCCCTATTGGCGTTACTATG
2442 GGAACATACGTCATTATTGACGTCAATGGGCGGGGGTCGTTGGGCGGTCAGCCAGGCGGGCCATTTACCGTAAG
PacI (2533)
SdaI (2525)
BspLU11I (2543)
2516 TTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAG
2588 GCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAG
2662 GTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTC
2736 CGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGC
ApaLI (2857)
2810 TGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGA
2884 CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAG
2958 CCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTAC
3032 GGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAG
3106 CTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAA
3180 AAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAA
PacI (3273)
3254 GGGATTTTGGTCATGGCTAGTTAATTAACATTTAAATCA